Piper Sandler downgraded Infinity Pharmaceuticals (INFI) to Neutral from Overweight with a price target of 30c, down from $3. Infinity announced its intention to merge with MEI Pharma (MEIP) and while the exchange ratio was not disclosed, Infinity shareholders are expected to own 42% of the combined company and MEI shareholders should own 58%, the analyst tells investors in a research note. The firm downgraded Infinity due to the merger.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MEIP:
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.
- MEI, Infinity report all-stock transaction to advance three oncology candidates
- MEI Pharma price target lowered to $2 from $5 at H.C. Wainwright
- MEI Pharma reports Q2 EPS 8c, consensus (14c)
- MEI Pharma downgraded to Underperform from Hold at Jefferies